The sea within us: Disorders of body water homeostasis

Current Opinion in Investigational Drugs

Volumn 8, Issue 4, 2007, Pages 304-311

  Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenal insufficiency; Aquaporin; Aquaretic; Hyponatremia; Hypothyroidism; Water channel

Indexed keywords

AQUAPORIN 2; CONIVAPTAN; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PHYSULINE; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN;

ADRENALECTOMY; BODY WATER; CLINICAL TRIAL; DEHYDRATION; DIURESIS; FLUID INTAKE; GLUCOCORTICOSTEROID DEFICIENCY; HOMEOSTASIS; HORMONE DEFICIENCY; HUMAN; HYPONATREMIA; HYPOPITUITARISM; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY CONCENTRATING CAPACITY; MINERALOCORTICOID DEFICIENCY; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PLASMA OSMOLALITY; POLYDIPSIA; POLYURIA; PROTEIN EXPRESSION; REVIEW; URINARY EXCRETION; URINE OSMOLALITY; VASOPRESSIN BLOOD LEVEL;

EID: 34147110737     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Verney EB: The antidiuretic hormone and the factors which determine its release. Proc R Soc Lond Biol (1947) 135(878):25-106. • This study provides compelling evidence for the existence of central osmoreceptors in regulating the release of antidiuretic hormone.
2. Du Vigneaud V, Gish DT, Katsoyannis PG: A synthetic preparation possessing biological properties associated with arginine vasopressin. J Am Chem Soc (1954) 76(18):4751-4752. •• This paper reports Nobel prize research identifying arginine vasopressin as mammalian antidiuretic hormone.
3. Schrier RW, Lieberman R, Ufferman RC: Mechanism of antidiuretic effect of β-adrenergic stimulation. J Clin Invest (1972) 51(1):97-111.
4. Schrier RW, Berl T: Mechanism of effect of α adrenergic stimulation with norepinephrine on renal water excretion. J Clin Invest (1973) 52(2):502-511.
5. Schrier RW, Berl T: Mechanism of the antidiuretic effect associated with interruption of parasympathetic pathways. J Clin Invest (1972) 51(10):2613-2620.
6. Berl T, Cadnapaphornchai P, Harbottle JA, Schrier RW: Mechanism of stimulation of vasopressin release during β adrenergic stimulation with isoproterenol. J Clin Invest (1974) 53(3):857-867. • This study demonstrated the role of arterial baroreceptors in the non-osmotic regulation of vasopressin during β-adrenergic stimulation.
7. Berl T, Cadnapaphornchai P, Harbottle JA, Schrier RW: Mechanism of suppression of vasopressin during α-adrenergic stimulation with norepinephrine. J Clin Invest (1974) 53(1):219-227. • This study demonstrated the role of arterial baroreceptors in the non-osmotic regulation of vasopressin during α-adrenergic stimulation.
8. Dunn FL, Brennan TJ, Nelson AE, Robertson GL: The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest (1973) 52(12):3212-3219. • This study demonstrated the relative sensitivity and potency of osmotic and non-osmotic regulation of vasopressin.
9. Kannan H, Yagi K: Supraoptic neurosecretory neurons: Evidence for the existence of converging inputs both from carotid baroreceptors and osmoreceptors. Brain Res (1978) 145(2):385-390.
10. 2 vasopressin receptor on the basolateral surface of principal cells in the collecting duct has allowed the identification of numerous receptor mutations leading to vasopressin-resistant NDI.
11. Sands JM, Bichet DG: Nephrogenic diabetes insipidus. Ann Intern Med (2006) 144(3):186-194.
12. r 30,000 integral membrane protein associated with the erythrocyte Rh(D) antigen. J Biol Chem (1987) 262(36):17497-17503. •• This paper and reference [13••] report the Nobel prize research, which identified the first membrane water channel, thereby opening a new era of investigation in water homeostasis.
13. Preston GM, Carroll TP, Guggino WB, Agre P: Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein. Science (1992) 256(5055):385-387. •• This paper and reference [12••] report the Nobel prize research, which identified the first membrane water channel, thereby opening a new era of investigation in water homeostasis.
14. Schrier RW: Body water homeostasis: Clinical disorders of urinary dilution and concentration. J Am Soc Nephrol (2006) 17(7):1820-1832. • A review analyzing the role of water channels, and ion and urea transporters to elucidate the mechanisms of clinical disorders of water homeostasis.
15. Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels. J Biol Chem (1998) 273(8):4296- 4299.
16. Ma T, Song Y, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels. Proc Natl Acad Sci USA (2000) 97(8):4386-4391.
17. Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J Clin Invest (1997) 100(5):957-962.
18. Nielsen S, Frokiaer J, Marples D, Kwon T-H, Agre P, Knepper MA: Aquaporins in the kidney: From molecules to medicine. Physiol Rev (2002) 82(1):205-244. • An excellent review of the role of AQP water channels in health and disease, describing the different roles of the seven AQPs expressed within the kidney.
19. Morello JP, Bichet DG: Nephrogenic diabetes insipidus. Annu Rev Physiol (2001) 63:607-630.
20. Bichet DG: Lithium, cyclic AMP signaling, A-kinase anchoring proteins, and aquaporin-2. J Am Soc Nephrol (2006) 17(4):920-922.
21. Manning M, Sawyer WH: Development of selective agonists and antagonists of vasopressin and oxytocin. In: Vasopressin. Schrier RW (Ed), Raven Press, New York, NY, USA (1985):131-144.
22. 2 antagonist which was effective in humans.
23. 2 vasopressin receptor antagonist in correcting hyponatremia in cardiac failure, cirrhosis and SIADH.
24. 2 receptor vasopressin antagonist, in the New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol (2006) 47(8):1615-1621.
25. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. J Am Med Assoc (2004) 291(16):1963-1971.
26. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J, VPA Study Group: Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology (2003) 124(4):933-939.
27. Verbalis JG: The syndrome of inappropriate antidiuretic hormone secretion and other hypo-osmolar disorders. In: Diseases of the Kidney and Urinary Tract. Schrier RW (Ed), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2006) 8:2214-2248.
28. Greenberg A, Verbalis JC: Vasopressin receptor antagonists. Kidney Int (2006) 69(12):2124-2130. • An up-to-date and critical review of studies examining the effect of vasopressin receptor antagonists in health and disease.
29. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104(20):2417-2423.
30. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, Saruta T, Yoshida S: Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab (1997) 82(4):1054-1057.
31. De Wardener HE, Herxheimer A: The effect of a high water intake on the kidney's ability to concentrate urine in man. J Physiol (1957) 139(1):42-52.
32. Cadnapaphornchai MA, Summer SN, Falk S, Thurman JM, Knepper MA, Schrier RW: Effect of primary polydipsia on aquaporin and sodium transporter abundance. Am J Physiol Renal Physiol (2003) 285(5):F965-F971. • This study demonstrated the effect of the downregulation of the AQP-2 water channel in a urinary-concentrating defect secondary to polydipsia.
33. 2 vasopressin receptor antagonist to demonstrate the role of non-osmotic vasopressin and the upregulation of AQP-2 in impaired water excretion in hypothyroidism.
34. Chen Y-C, Cadnapaphornchai MA, Summer SN, Falk S, Li C, Wang W, Schrier RW: Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol (2005) 16(10):2864-2871.
35. Oelkers W: Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med (1989) 321(8):492-496.
36. 2 vasopressin receptor antagonist to demonstrate the role of non-osmotic vasopressin and the upregulation of AQP-2 in impaired water excretion in hypothyroidism.
37. Ufferman RC, Schrier RW: Importance of sodium intake and mineralocorticoid hormone in the impaired water excretion in adrenal insufficiency. J Clin Invest (1972) 51(7):1639-1646.
38. Ohara M, Cadnapaphornchai MA, Summer SN, Falk S, Yang J, Togawa T, Schrier RW: Effect of mineralocorticoid deficiency on ion and urea transporters and aquaporin water channels in the rat. Biochem Biophy Res Commun (2002) 299(2):285-290.
39. Ishikawa S, Schrier RW: Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats. Kidney Int (1982) 22(6):587-593.
40. Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S: Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest (1995) 95(4):1838-1845. • This paper and references [41•,42•,43•,44•,45•] report the effect of the downregulation of AQP-2 expression in acquired NDI.
41. Marples D, Frokiaer J, Dorup J, Knepper MA, Nielsen S: Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest (1996) 97(8):1960-1968. • This paper and references [40•,42•, 43•,44•,45•] report the effect of the downregulation of AQP-2 expression in acquired NDI.
42. Earm JH, Christensen BM, Frokiaer J, Marples D, Han JS, Knepper MA, Nielsen S: Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol (1998) 9(12):2181-2193. • This paper and references [40•,41•,43•,44•,45•] report the effect of the downregulation of AQP-2 expression in acquired NDI.
43. Frokiaer J, Marples D, Knepper MA, Nielsen S: Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. Am J Physiol (1996) 270 (4 Pt 2):F657-F668. • This paper and references [40•,41•,42•, 44•,45•] report the effect of the downregulation of AQP-2 expression in acquired NDI.
44. Kwon TH, Frokiaer J, Fernandez-Llama P, Knepper MA, Nielsen S: Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: Prevention by α-MSH. Am J Physiol (1999) 277(3 Pt 2):F413-F427. • This paper and references [40•,41•, 42•,43•,45•] report the effect of the downregulation of AQP-2 expression in acquired NDI.
45. Kwon TH, Frokiaer J, Knepper MA, Nielsen S: Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol (1998) 275(5 Pt 2):F724-F741. • This paper and references [40•,41•,42•,43•,44•] report the effect of the downregulation of AQP-2 expression in acquired NDI.
46. Astellas Pharma US Inc: Astellas launches Vaprisol for the treatment of euvolemic hyponatremia in hospitalized patients. Press Release (2006): April 26.
47. 2-receptor antagonist. Press Release (2006): October 11.
48. sanofi-aventis: Annual Report 2004 - sanofi-aventis. Annual Report (2005): March 31.
49. Otsuka Maryland Research Institute Inc - pipeline. Otsuka Pharmaceutical Co Ltd, Tokyo, Japan (2004). http://www.otsuka.com/OMRI/ OMRIPipeline.htm
50. Cardiokine Inc: Cardiokine Inc completes $37 million private equity financing. Press Release (2004): April 13.